PTAB institutes IPRs on Sanofi patents
Copyright © 2009-2014 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, N.J., U.S.A. All rights reserved.
Sanofi has filed a complaint against Merck for allegedly infringing ten of its patents centring on the diabetes drugs Lantus (insulin glargine injection) and Lantus SoloSTAR.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at email@example.com
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Sanofi, Merck, Lantus, Lantus SoloStar, patent, NDA